DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $947 | -15.1% | 3,816 | -17.9% | 0.45% | +7.8% |
| Q2 2023 | $1,115 | +0.5% | 4,646 | +5.5% | 0.42% | -7.9% |
| Q1 2023 | $1,110 | -21.9% | 4,404 | -17.7% | 0.46% | -27.1% |
| Q4 2022 | $1,421 | -99.9% | 5,353 | +14.7% | 0.63% | +9.8% |
| Q3 2022 | $1,205,000 | +6.6% | 4,667 | +4.7% | 0.57% | +12.0% |
| Q2 2022 | $1,130,000 | -25.0% | 4,458 | -13.2% | 0.51% | +6.2% |
| Q1 2022 | $1,506,000 | -23.2% | 5,134 | -13.8% | 0.48% | -6.8% |
| Q4 2021 | $1,960,000 | +8.0% | 5,958 | 0.0% | 0.52% | -2.5% |
| Q3 2021 | $1,814,000 | -0.4% | 5,958 | -12.2% | 0.53% | +13.8% |
| Q2 2021 | $1,821,000 | +23.9% | 6,786 | +3.9% | 0.46% | +14.0% |
| Q1 2021 | $1,470,000 | -83.4% | 6,532 | -83.6% | 0.41% | -8.3% |
| Q4 2020 | $8,834,000 | +1.2% | 39,768 | -1.9% | 0.44% | -8.5% |
| Q3 2020 | $8,728,000 | +34.5% | 40,534 | +10.5% | 0.48% | +22.8% |
| Q2 2020 | $6,488,000 | +15.9% | 36,692 | -9.3% | 0.40% | -4.4% |
| Q1 2020 | $5,598,000 | +2.4% | 40,444 | +13.6% | 0.41% | +26.7% |
| Q4 2019 | $5,465,000 | +6.3% | 35,605 | 0.0% | 0.33% | -3.0% |
| Q3 2019 | $5,142,000 | -7.2% | 35,605 | -8.2% | 0.34% | -8.4% |
| Q2 2019 | $5,543,000 | +11.0% | 38,781 | +2.6% | 0.37% | +6.1% |
| Q1 2019 | $4,992,000 | +21.6% | 37,811 | -5.0% | 0.35% | +16.5% |
| Q4 2018 | $4,105,000 | -7.5% | 39,812 | -2.5% | 0.30% | +10.0% |
| Q3 2018 | $4,437,000 | +10.1% | 40,838 | 0.0% | 0.27% | +2.7% |
| Q2 2018 | $4,030,000 | -8.1% | 40,838 | -8.8% | 0.26% | -1.1% |
| Q1 2018 | $4,385,000 | -3.6% | 44,786 | -8.6% | 0.27% | +7.3% |
| Q4 2017 | $4,550,000 | +8.2% | 49,019 | -0.0% | 0.25% | +57.0% |
| Q3 2017 | $4,206,000 | +7.7% | 49,038 | +5.9% | 0.16% | +2.6% |
| Q2 2017 | $3,907,000 | -1.4% | 46,294 | -0.1% | 0.15% | -4.9% |
| Q1 2017 | $3,964,000 | +5.0% | 46,349 | -4.5% | 0.16% | +1.9% |
| Q4 2016 | $3,777,000 | +3.5% | 48,519 | +4.2% | 0.16% | 0.0% |
| Q3 2016 | $3,651,000 | -21.6% | 46,581 | +1.0% | 0.16% | -22.1% |
| Q2 2016 | $4,656,000 | +6.3% | 46,099 | -0.2% | 0.20% | +3.0% |
| Q1 2016 | $4,381,000 | +4.1% | 46,181 | +1.9% | 0.20% | +2.1% |
| Q4 2015 | $4,208,000 | +41.4% | 45,311 | +29.8% | 0.19% | +32.0% |
| Q3 2015 | $2,976,000 | -23.9% | 34,921 | -23.6% | 0.15% | -20.1% |
| Q2 2015 | $3,913,000 | +17.2% | 45,721 | +16.2% | 0.18% | +16.5% |
| Q1 2015 | $3,339,000 | +19.4% | 39,332 | +20.5% | 0.16% | +16.2% |
| Q4 2014 | $2,797,000 | +12.8% | 32,632 | 0.0% | 0.14% | +7.1% |
| Q3 2014 | $2,479,000 | -1.7% | 32,632 | +1.8% | 0.13% | -2.3% |
| Q2 2014 | $2,523,000 | -2.2% | 32,050 | -6.8% | 0.13% | -4.4% |
| Q1 2014 | $2,580,000 | -0.8% | 34,400 | +2.1% | 0.14% | -2.9% |
| Q4 2013 | $2,602,000 | +71.4% | 33,700 | +53.9% | 0.14% | +55.6% |
| Q3 2013 | $1,518,000 | +23.6% | 21,900 | +12.9% | 0.09% | +26.8% |
| Q2 2013 | $1,228,000 | – | 19,400 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |